Novo Nordisk slashes US prices for Ozempic, Wegovy, and Rybelsus to $675/month in 2027. Its new obesity drug, CagriSema, trails Eli Lilly’s Zepbound in a key trial.
The Danish pharmaceutical giant Novo Nordisk finds itself navigating a period of significant pressure. The company is contending with dual challenges: a substantial planned price reduction for its key drugs in the United States and a clinical trial setback for a next-generation treatment. These developments arrive as the firm seeks to rebuild investor confidence following a difficult 2025.
Strategic Price Reductions Set for 2027
In a major strategic shift, Novo Nordisk has announced it will significantly lower the list prices for its portfolio of GLP?1 medications—Ozempic, Wegovy, and Rybelsus—in the U.S. market. Effective January 1, 2027, the company will implement a uniform monthly Wholesale Acquisition Cost of $675.
This change represents a substantial discount from current levels. The price for Wegovy is expected to be nearly halved, falling from $1,349.02 to the new $675 benchmark. For Ozempic injections and Rybelsus tablets, the reduction equates to approximately 34%, down from $1,027.51.
Company statements indicate the primary motivation is to improve patient access. Individuals facing high deductibles or coinsurance payments are often directly impacted by the list price. Lowering this benchmark should consequently reduce out-of-pocket expenses. The timing aligns with the anticipated introduction of significantly lower negotiated prices for the U.S. Medicare system, reportedly around $274 per month.
Clinical Trial Disappointment Intensifies Competitive Landscape
Shortly after the pricing news, the company faced another hurdle from its development pipeline. Data from a head-to-head study revealed that its next-generation obesity treatment, CagriSema, failed to meet the key goal of demonstrating non-inferiority to Eli Lilly’s rival drug, Tirzepatid (marketed as Zepbound), after 84 weeks of treatment.
The study results showed a 23% weight loss for patients on CagriSema (2.4 mg) compared to 25.5% for those on Tirzepatid (15 mg). Novo Nordisk’s research chief, Martin Holst Lange, pointed to the study’s open-label design as a potential factor, noting that such a format—where participants know which drug they are receiving—can introduce bias, particularly when a well-established therapy is compared to an investigational one.
Despite this setback, CagriSema is not being abandoned. Novo Nordisk submitted the drug for FDA approval late last year, with a decision expected by the end of 2026. Furthermore, the company plans to initiate a Phase III trial with a higher dosage in the second half of 2026 and is evaluating additional studies involving higher-dose combinations.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Confluence of Pressures: Growth, Patents, and Market Share
The pricing strategy and clinical results come against a backdrop of increasing market pressures. Novo Nordisk acknowledges a more intense competitive environment, highlighting that Eli Lilly’s revenue growth over the past three years (135%) has significantly outpaced its own (77%). Concurrently, the impending expiration of Semaglutid patents in certain markets, including Brazil, Canada, and China, clouds the outlook for 2026. Market share is also being pressured by competing products and providers of compounded preparations.
The company’s own guidance reflects this cautious stance. For 2026, Novo Nordisk forecasts a decline in both sales and operating profit of between 5% and 13%, assuming constant exchange rates.
Share Buyback Program Continues Amid Market Weakness
Despite the headwinds, the company remains committed to returning capital to shareholders. A share repurchase program of up to 15 billion Danish kroner, launched on February 4, 2026, is currently underway. By February 20, the company had repurchased 2,750,000 B shares at an average price of 306.18 DKK, for a total value of approximately 842 million DKK.
The tense situation is clearly reflected in the equity markets. The share price closed at a 52-week low of €31.68 on Friday, marking a decline of 62.82% over the preceding 12-month period.
Attention now turns to the Annual General Meeting scheduled for March 26, 2026. A key agenda item will be seeking renewed shareholder approval to continue the share buyback program beyond March 2026—a critical vote occurring at a time when pricing pressures, pipeline questions, and fierce competition collectively weigh on the stock.
Ad
Novo Nordisk Stock: New Analysis – 2 March
Fresh Novo Nordisk information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.
Read our updated Novo Nordisk analysis…
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen – dreimal pro Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr.
Jetzt abonnieren.